Quantcast

Latest Biologic Stories

2014-05-05 12:28:40

European Dermatologists Indicate that Fewer than Half of Their Severe Patients are being Treated with a Biologic, According to Findings from Decision Resources Group BURLINGTON, Mass., May 5, 2014 /PRNewswire/ -- Decision Resources Group finds that the use of biologics for the treatment of psoriasis among dermatologists has remained relatively flat since 2011 in the major European markets (France, Germany, Italy, Spain and the United Kingdom), with less than half of severe patients being...

2014-05-05 08:28:53

TARRYTOWN, N.Y. and MENLO PARK, Calif., May 5, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Avalanche Biotechnologies, Inc., today announced the formation of a broad collaboration to discover, develop and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The collaboration covers novel gene therapy vectors and proprietary molecules, discovered jointly by Avalanche and Regeneron, and developed using the Avalanche Ocular...

2014-05-05 08:28:08

SHANGHAI and TAIPEI, May 5, 2014 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX) and TaiMed Biologics today announced that the FDA has approved the first batch of the ibalizumab (TMB-355) drug substance and sterile drug product manufactured at WuXi's biologics facilities for ongoing treatment of patients under investigator-sponsored IND's. This is the first reported FDA approval of a sterile biologics product manufactured in China for use under a U.S. IND, which marks an important...

2014-05-05 00:21:27

COVA322 is First of Covagen's Bispecific FynomAbs to Enter Clinical Trials ZURICH-SCHLIEREN, Switzerland, May 5, 2014 /PRNewswire/ -- Covagen today announced it has initiated a Phase Ib/IIa study with COVA322, a bispecific TNF/IL-17A inhibitor. COVA322 is Covagen's lead bispecific FynomAb® developed for treatment of patients with rheumatoid arthritis, psoriatic arthritis and other inflammatory diseases. The trial will enroll 39 patients with psoriasis and evaluate safety as well as...

2014-05-02 23:00:27

The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides (http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html). (PRWEB) May 03, 2014 Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast...

2014-04-30 08:33:09

Proprietary "Smart Antibodies" Allow for Selective Activation in Cancerous Tissues SAN DIEGO, April 30, 2014 /PRNewswire/ -- BioAtla, a global biotechnology company focused on the development of differentiated biological therapeutics, today announced that the United States Patent and Trademark Office (USPTO) has issued to BioAtla U.S. Patent No. 8,709,755, its first patent directed to methods of generating conditionally active antibodies. Conditionally active antibodies are...

2014-04-30 08:31:49

-- Conference Call Scheduled for Today, April 30, 2014 at 9 AM ET-- ROCKVILLE, Md., April 30, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, will host a conference call today to discuss in further detail the topline Phase II study results of Trimesta(TM) (oral estriol), which the Company is developing as a once-daily adjunctive...

2014-04-29 23:22:06

Gallus BioPharmaceuticals, a premier pure-play biologics contract development and manufacturing organization and Omni Bio Pharmaceutical, a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT), jointly announced finalization of a multi-stage manufacturing services agreement. St. Louis, Missouri (PRWEB) April 29, 2014 Gallus BioPharmaceuticals, LLC(Gallus), a premier pure-play biologics contract development and manufacturing...

2014-04-29 08:36:38

BEIJING, April 29, 2014 /PRNewwire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release first quarter 2014 financial results on Tuesday, May 6, 2014 after the market closes. The Company's management will hold a conference call at 8:00 a.m. ET on Wednesday, May 7, 2014, which is 8:00 p.m., Beijing Time on May 7, 2014, to discuss...

2014-04-28 08:31:55

REDWOOD CITY, Calif., April 28, 2014 /PRNewswire/ -- Coherus Biosciences, Inc. ("Coherus"), is pleased to announce the appointment of Michael A. Fleming as Senior Vice President, Commercial Strategy. Mr. Fleming joins Coherus with more than 25 years of experience in strategic and operational leadership roles at preeminent biotech companies. "Michael is a vital addition to the Coherus team at this time," said Denny Lanfear, President and CEO of Coherus. "Our pipeline is now...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related